Avastin (bevacizumab) is a type of chemotherapy treatment that slows tumor growth by blocking the protein that is responsible for forming new blood vessels, which is what tumors need to thrive. By blocking these blood vessels, tumor growth is slowed. For those suffering from mesothelioma, hindering tumor growth can greatly[…]
From the blog
Less than Half of Cancer Patients Eligible for Immunotherapy Treatments
In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer. It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma.[…]
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
This is a dose escalation (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of Nap with durvalumab in subjects with selected advanced or metastatic solid tumors.
Potential New Treatment Acts as a Sealant for Pleural Mesothelioma Tumors
Pleural mesothelioma, caused by exposure to asbestos is a rare cancer – only 3,000 cases are diagnosed in the U.S. each year – but it is highly aggressive. There is no cure for plural mesothelioma but findings published in the Journal of Thoracic and Cardiovascular Surgery reveal that a new[…]
Mesothelioma Patients Not Receiving Treatment Impacts Guidelines and Overall Survival
A mesothelioma diagnosis can be grim and have life-long impact on the patients and family. The aggressive nature and the late diagnosis of the disease make it difficult to treat. The average life expectancy after initial diagnosis is on average one year, but with treatment – especially multimodality treatments –[…]
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in subjects with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design followed by a Phase 2 study.
First FDA Approved Treatment for Mesothelioma in 15 Years
In the Fall of 2018 scientists and researchers from Novocure, an oncology company that specializes in treating solid tumors, were hopeful their latest success with Tumor Treating Fields therapy would lead to FDA approval and ultimately, more options for those suffering from mesothelioma. After a successful clinical trial, these hopes[…]
Currently Recruiting: Mesothelioma Clinical Trials
When it comes to effective mesothelioma treatments, options are unfortunately limited. There is no cure for mesothelioma and first line chemotherapy treatment Alimta, is no guarantee. Many who are suffering from mesothelioma, who have found little or no comfort in traditional treatments, may turn to clinical trials for hope. Through[…]
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.
